Paid-in Capital Increase Amendment
진원생명과학
011000
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2719
Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Event: Paid-in Capital Increase
AI Analysis Summary
GeneOne Life Science, Inc. announced an amendment to its Material Fact Report regarding a decision on a paid-in capital increase. This event typically leads to share dilution, negatively impacting existing shareholder value. The specific terms of the increase, such as the number of new shares and issuance price, are not available from the title alone, but a capital increase generally suggests a need for funding, which can be viewed as a negative signal without clear justification for growth.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.